Keyword: Gilead Sciences


Gilead to Buy Liver Drugmaker CymaBay for $4.3 Billion

13.02.2024 -

US biopharmaceutical company Gilead Sciences is to acquire CymaBay Therapeutics for $4.3 billion. Gilead offered to purchase all outstanding shares of CymaBay for $32.50...


Gilead and Compugen Strike Exclusive Deal for New Immunotherapy Program

22.12.2023 -

Gilead has exclusive rights for the advancement and commercialization of anti-IL18 binding protein antibodies targeting various tumor types. Gilead commits to a...


Gilead Partners with Tentarix on Cancer and Inflammation Therapies

17.08.2023 -

Gilead Sciences and Tentarix Biotherapeutics established three multi-year collaborations using Tentarix’s proprietary Tentacles platform to discover and develop multi...


Gilead Buys Oxford Spin-out MiroBio

10.08.2022 -

Gilead Sciences has agreed to acquire MiroBio, a privately held UK biotech focused on treating inflammatory diseases, for about $405 million in cash.


BioNTech Buying Cell Therapy Plant from Kite

21.07.2021 -

Germany’s BioNTech, best known publicly for the Covid-19 vaccine Comirnaty it developed in partnership with US drugs giant Pfizer, has announced plans to buy a cell...

Chemistry & Life Sciences

Innovation and Creativity in the Pharmaceutical Industry

30.04.2021 -

The International Society for Pharmaceutical Engineering (ISPE) announced the 2021 Facility of the Year Awards (FOYA) Category Winners—including two winners of Special...


Drugs and Maybe Covid Vaccines Headed to India

28.04.2021 -

As India’s Covid-19 infections soar and the death toll nears 200,000, wealthier countries – including the US, UK, Germany, France and Australia – are rushing supplies of...


Gilead Takes Immunomedics for $21 Billion

16.09.2020 -

Gilead Sciences is to acquire Immunomedics for approximately $21 billion. The deal, unanimously approved by both companies' boards of directors, will be funded by $15...